In this work, we designed the tumor–targeted cRGD–PaNPs–αPD–L1 loading Pa and αPD–L1 for the combined PDT and PD–L1 blockade therapy of a 4T1 tumor with a low PD–L1 expression. Here, CD274 is linked to neoplasm.